This Small Research Grant Program supports important and innovative research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, treatment and care for Alzheimer's disease and related dementias. The program seeks to stimulate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, Alzheimer's disease and healthy brain aging.
This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimer's disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.
This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.
The PRARP Quality of Life Research Award (QUAL) mechanism was first offered in FY13. Since then, 38 QUAL applications have been received, and 16 have been recommended for funding. The intent of the research funded through this award is to (1) support research to alleviate, stabilize, or characterize the symptoms or deficits common to TBI and AD/ADRD, and (2) reduce the burden of care on the caregiver for individuals living with the common symptoms of TBI and AD/ADRD. Research may be proposed to either facet of the intent. Both are equally important. As part of the research strategy, all applications must include cognitive, neuropsychological, or otherwise appropriate measures. The FY17 PRARP QUAL is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI's published work, pilot data, or from peer-reviewed literature. Applications should also address how all of the included study measures address the research strategy and the study's hypothesis or hypotheses. The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP QUAL will not exceed $500,000. The maximum period of performance is 3 years.
This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimers disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.
Deprescribing, the cessation of long-term therapy under clinician supervision, is a fundamental technique of geriatric practice and palliative medicine to address inappropriate medication use and/or polypharmacy common among older adults with multimorbidity. Important research gaps remain whose resolution may improve approaches to deprescribing and may improve health outcomes by optimizing the goal-directed care of older adults with multiple chronic conditions. This FOA is intended to support a collaborative network to advance scientific research into techniques and outcomes of deprescribing medications for prevention and treatment of older adults with multiple chronic conditions. This network should address the scientific, safety, ethical, and logistical challenges of deprescribing trials and may incorporate focused attention to other relevant and well-justified topics, such as the risks and benefits of target medications, or alternative approaches that may substitute for the deprescribed drugs. This FOA will support the establishment and initial operations of a network over the 5-year grant period including development of collaborations, resources, and infrastructure.
Deprescribing, the cessation of long-term therapy under clinician supervision, is a fundamental technique of geriatric practice and palliative medicine to address inappropriate medication use and/or polypharmacy common among older adults with multi-morbidity. Important research gaps remain whose resolution may improve approaches to deprescribing and may improve health outcomes by optimizing the goal-directed care of older adults with multiple chronic conditions. This FOA is intended to support a collaborative network to advance scientific research into techniques and outcomes of deprescribing medications for prevention and treatment of older adults with multiple chronic conditions. This network should address the scientific, safety, ethical, and logistical challenges of deprescribing trials and may incorporate focused attention to other relevant and well-justified topics, such as the risks and benefits of target medications, or alternative approaches that may substitute for the deprescribed drugs.
The Administration on Aging will hold a competition for a new cooperative agreement to continue operation of a national information and counseling service for persons with Alzheimer's disease, their family members and caregivers (National Alzheimer's Call Center). The National Call Center will be available to people in 56 states and territories, 24 hours a day, 7 days a week, 365 days a year to provide expert advice, care consultation, information and referrals at the national and local levels, regarding Alzheimer's disease and related dementias (ADRD).
This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as well as the Roybal Centers for Translational Research on Dementia Care Provider Support program. The Roybal Coordinating Center will serve as a hub for the Roybal Center grant program. Roybal Center programs conduct translational research in the behavioral and social sciences of aging, structured in accordance with the NIH Stage Model. Roybal Center program resources are intended for pilot and preliminary translational, multi-directional research at Stages 0 through IV of the behavioral intervention development pipeline with the goal of creating principle-driven interventions that improve the lives of mid-life and older people and the capacity of institutions to adapt to societal aging. The Roybal Coordinating Center will facilitate and coordinate trans-Roybal activities. The Center will work closely with the NIA Program Officer and, in coordination with all Roybal sites, will be responsive to requests generated by key Roybal site personnel, NIA, NIH, the scientific community, and the general public.
This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as well as the Roybal Centers for Translational Research on Dementia Care Provider Support program. The Roybal Coordinating Center will serve as a hub for the Roybal Center grant program. Roybal Center programs conduct translational in the behavioral and social sciences of aging, structured in accordance with the NIH Stage Model. Roybal Center program resources are intended for pilot and preliminary translational, multi-directional research at Stages 0 through IV of the behavioral intervention development pipeline with the goal of creating principle-driven interventions that improve the lives of mid-life and older people and the capacity of institutions to adapt to societal aging. The Roybal Coordinating Center will facilitate and coordinate trans-Roybal activities. The Center will work closely with the NIA Program Officer and, in coordination with all Roybal sites, will be responsive to requests generated by key Roybal site personnel, NIA, NIH, the scientific community, and the general public.
The goal of this FOA is to support short courses geared to behavioral and social scientists who have existing expertise in aging research and can make research contributions in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) with additional knowledge about the disease and related research resources. Fields of behavioral and social science research relevant for this FOA are health economics, labor economics, health services research, healthcare policy, public policy, demography, sociology, social epidemiology, psychology, and social neuroscience. Priority areas of focus include, but are not limited to, the following: dementia care; dementia caregiver research; cognitive and dementia epidemiology; behavioral and social pathways of AD/ADRD; role of social, contextual, environmental, and institutional factors in AD/ADRD; early psychological changes preceding AD/ADRD onset; prevention of AD/ADRD; disparities in AD/ADRD or dementia-related outcomes; and research resources and methods for studying the determinants and impact of AD/ADRD.
The purpose of NIDILRR's Disability and Rehabilitation Research Projects (DRRP) which are funded through the Disability and Rehabilitation Research Projects and Centers Program, is to plan and conduct research, demonstration projects, training, and related activities, including international activities, to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities, and to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Rehabilitation Act).
Under this particular DRRP priority, the objective is to improve long-term health outcomes of people with traumatic brain injury (TBI). The grantee will conduct research at the intervention-development stage, to directly inform and shape the development of chronic disease management approaches for meeting the complex and varied health care needs of people with TBI.
The Brookdale National Group Respite Program awards seed grants to service providers that plan to develop new, dementia-specific Group Respite or specialized Early Memory Loss (EML) programming to participants, along with support to caregivers and care partners. All funded programs must provide a social model day program for people affected by Alzheimer's disease or other dementia. Up to 15 organizations will receive grants of $10,000 in year one, renewable for $5,000, based on evaluation of the first year's activities and potential for future continuity of the program. The application deadline is June 24, 2020. Visit the Brookdale Foundation Group's website to download the guidelines and application form.
This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers (ADRCs). NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimers disease and Alzheimer's disease-related dementias (AD/ADRD) and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.
This funding opportunity is for competitive grants to be awarded under the OAA Title IV authority to increase the evidenced based knowledge base of nutrition providers, drive improved health outcomes for program recipients by promoting higher service quality, and increase program efficiency through innovative nutrition service delivery models. Funding will support innovative and promising practices that move the aging network towards evidenced based practices that enhance the quality, effectiveness of nutrition services programs or outcomes within the aging services network. Innovation can include service products that appeal to caregivers (such as web-based ordering systems and carryout food products), increased involvement of volunteers (such as retired chefs), consideration of eating habits and choice (such as variable meal times, salad bars, or more fresh fruits and vegetables), new service models (testing variations and hybrid strategies) and other innovations to better serve a generation of consumers whose needs and preferences are different. Innovation and promising practices may include the testing and publishing of positive outcomes in which nutrition programs provide a meaningful role in support of the health and long-term care of older individuals.
The intent of the research funded through this award is to (1) support research to alleviate, stabilize, or characterize the symptoms or deficits common to TBI and AD/ADRD, and (2) reduce the burden of care on the caregiver for individuals living with the common symptoms of TBI and AD/ADRD. Research may be proposed to either facet of the intent. Both are equally important. As part of the research strategy, all applications must include cognitive, neuropsychological, or otherwise appropriate measures.The FY17 PRARP QUAL is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI's published work, pilot data, or from peer-reviewed literature. Applications should also address how all of the included study measures address the research strategy and the study's hypothesis or hypotheses.The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP QUAL will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.The research impact is expected to benefit the military, Veteran, and civilian communities. To this end, the PRARP has identified QUAL Overarching Challenges and Focus Areas by which the intent of this mechanism can be facilitated. These should be carefully considered as part of the application process.FY17 PRARP QUAL Overarching Challenges: T
The involvement of small businesses in translational aging research could substantially hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults. Therefore, this funding opportunity announcement (FOA) is intended to encourage a greater involvement by small businesses through the SBIR mechanism in transforming scientific advances in aging research into novel devices, products, health care practices and programs that will benefit the lives of older adults.
For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical or basic behavioral and social research findings towards the development of new strategies for prevention and treatment of age-related pathologies. T1 translational research approaches could include the development of new research tools or improving existing technologies to diagnose, prevent or treat age-related conditions, functional decline and disability.
Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains. Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of, and develop effective treatments for, AD by 2025. As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-fy2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits and milestones published in the FY2017 Alzheimer's disease bypass budget to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD.
Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains. Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across all regions of the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of and develop effective treatments for AD by 2025. As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-FY 2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD.
The Communities Building Healthier Environments for a Stronger Nation Initiative ('Communities Initiative') intends to demonstrate the effectiveness of community-based networks in improving health outcomes among racial and ethnic minority and/or other disadvantaged populations. This program seeks to improve health outcomes through the establishment of integrated networks that collaboratively employ evidence-based disease management and preventive health activities; build the capacity of communities to address social determinants and barriers to healthcare access; and increase access to and utilization of preventive health care, medical treatment, and supportive services. The Communities Initiative specifically targets the unmet healthcare and supportive service needs of racial and ethnic minority populations at highest risk for poorer health outcomes. Health services provided under the Communities Initiative will not be denied to any person based on race, color, or national origin. Populations at highest risk include, but are not limited to, individuals who are newly diagnosed and lack a medical home; individuals who experience difficulty in adhering to a prescribed medical treatment plan; individuals with a chronic disease that is not well managed; and individuals that are unstably housed. Specific health areas to be addressed by the Communities Initiative include asthma, cardiovascular disease, diabetes, HIV/AIDS, Hepatitis B or C, obesity/overweight, and mental disorders. Community health programs are required to address social determinants of health, and improve coordination of health, social, and supportive services to significantly improve health outcomes among minority and/or disadvantaged communities. Applicants must choose two but no more than three chronic conditions
Group items tagged 
